Patent US4650796A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4650796A Expired / Lapsed US ⏱️ 0.0 years remaining

3-acylaminomethylimidazo[1,2-a]pyridine derivatives and pharmaceutical compositions containing them

Assignee: Sanofi Aventis France
•
Filing: 1986-02-07
•
Granted: 1987-03-17
•
Expires: 2006-02-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds which are imidazo[1,2-a]pyridine derivatives of general formula (I) ##STR1## in which each of X 1 , X 2 , X 3 , independently of each other, is hydrogen, halogen, C 1 -C 4 alkyl, methoxy, methylthio, ethylthio, methylsulphonyl, nitro, amino, methylamino, dimethylamino, acetylamino or diacethylamino, Y is hydrogen, chlorine or methyl, R 1 is hydrogen, C 1 -C 4 alkyl or benzyl, R 2 is C 1 -C 6 alkyl, cyclohexyl, trichloromethyl, 1-propenyl, allyl, phenyl, 4-chlorophenyl or benzyl, or R 1 and R 2 together represent a divalent C 3 -C 5 alipathic group and their pharmaceutically acceptable acid salts have anxiolytic, sleep-inducing, hypnotic, anticonvulsant, analgesic and anti-ulcer properties.

Inventors

  • 👤 Pascal George
  • 👤 Claude Giron

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 05:29
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04; A; A61; A61P; A61P25/00; A61P25/08; A61P25/20; A61P25/28

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 102 words
Imidazo[1,2-a]pyridine of the formula ##STR10## in which each of X 1 , X 2 , X 3 , independently of each other is hydrogen, halogen, C 1 -C 4 alkyl, methoxy, methylthio, ethylthio, methylsulphonyl, nitro, amino, methylamino, dimethylamino, acetylamino and diacetylamino, Y is selected from hydrogen, chlorine and methyl, R 1 is selected from hydrogen, C 1 -C 4 alkyl and benzyl, R 2 is selected from C 1 -C 6 akyl, cyclohexyl, trichloromethyl, 1-propenyl, allyl, phenyl, 4-chlorophenyl and benzyl, or R 1 and R 2 together represent a divalent C 3 -C 5 aliphatic group, and their pharmaceutically acceptable acid salts.
Claim 2
Dependent Claim 102 words
Imidazo[1,2-a]pyridine of the formula ##STR10## in which each of X 1 , X 2 , X 3 , independently of each other is hydrogen, halogen, C 1 -C 4 alkyl, methoxy, methylthio, ethylthio, methylsulphonyl, nitro, amino, methylamino, dimethylamino, acetylamino and diacetylamino, Y is selected from hydrogen, chlorine and methyl, R 1 is selected from hydrogen, C 1 -C 4 alkyl and benzyl, R 2 is selected from C 1 -C 6 akyl, cyclohexyl, trichloromethyl, 1-propenyl, allyl, phenyl, 4-chlorophenyl and benzyl, or R 1 and R 2 together represent a divalent C 3 -C 5 aliphatic group, and their pharmaceutically acceptable acid salts.
Claim 3
Dependent Claim 51 words
Compound according to claim 1, wherein at least one of X 1 , X 2 and X 3 is selected from chlorine, methyl, methoxy and methylthio, Y is selected from hydrogen, chlorine and methyl, R 1 is selected from hydrogen and methyl, and R 2 is selected from propyl and isobutyl.
Claim 4
Dependent Claim 24 words
An anxiolytic pharmaceutical composition which comprises an effective amount of a compound as claimed in claim 1 in association with a pharmaceutically acceptable excipient.
Claim 5
Dependent Claim 26 words
A sleep-inducing or hypnotic pharmaceutical composition which comprises an effective amount of a compound as claimed in claim 1 in association with a pharmaceutically acceptable excipient.
Claim 6
Dependent Claim 24 words
An anticonvulsant pharmaceutical composition which comprises an effective amount of a compound as claimed in claim 1 in association with a pharmaceutically acceptable excipient.
Claim 7
Dependent Claim 24 words
An analgesic pharmaceutical composition which comprises an effective amount of a compound as claimed in claim 1 in association with a pharmaceutically acceptable excipient.
Claim 8
Dependent Claim 24 words
An anti-ulcer pharmaceutical composition which comprises an effective amount of a compound as claimed in claim 1 in association with a pharmaceutically acceptable excipient.

References Cited (Backward Citations)

GB1076089A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-03-16 1990-09-15 1991-03-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-03-16 1994-09-15 1995-03-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-03-16 1998-09-15 1999-03-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag